000			nab a22 7a 4500
999			_c15926 _d15926
003			PC15926
005			20210218131510.0
008			200513b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92662 _aDa Silva Rodríguez, Carolina _eHematología y Hemoterapia
245	0	0	_aBendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. _h[artículo]
260			_bAnnals of hematology, _c2014
300			_a93(9):1551-8.
500			_aFormato Vancouver: García-Noblejas A, Martínez Chamorro C, Navarro Matilla B, Da Silva Rodríguez C, González-López TJ, Oña Navarrete R et al. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. Ann Hematol. 2014 Sep;93(9):1551-8.
501			_aPMID: 24782117
504			_aContiene 29 referencias
520			_aPatients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with bendamustine in combination or alone with the objective of knowing the efficacy and toxicity profile of this treatment in our current clinical practice. Fifty eight patients were registered: 67 % male with median age of 71 years, and 2 is the median number of previous lines. The most frequent bendamustine regimen was bendamustine plus rituximab (83 %). The median number of cycles was 5 (range 1-8). The overall response rate was 84 % with 53 % of complete response/unconfirmed complete response (CR/uCR). Median progression-free survival (PFS) was 16 months (95 % confidence interval (CI) 13.3-18.8), and for patients who achieved CR/uCR, it was 33 months (95 % CI 11.1-54.2). Median overall survival (OS) was 30 months (95 % CI 25.6-34.9). For PFS, only blastoid histology and not achieving CR after bendamustine had a significant negative impact on the univariate and multivariate analyses (p < 0.05). Nevertheless, for OS, only an elevated lactate dehydrogenase (LDH) had negative impact on both, univariate and multivariate analyses (p < 0.05). Only one case of treatment-related mortality in a 79-year-old patient with very bad performance status was reported. In 280 cycles, 12 (4 %) hospitalizations for febrile neutropenia were reported. In our population, bendamustine has been a good salvage treatment with a favorable toxicity profile in a non selected and heavily pretreated population of patients with MCL.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc15926.pdf _ySolicitar documento
942			_2ddc _cART _n0